P20RR015592/RR/NCRR NIH HHS/United States[Grants and Funding] - Search Results

Year	Number of Results
2003	2
2004	3
2005	4
2006	4
2007	3
2008	1
2012	1
2024	0

1

Molecular targets of opiate drug abuse in neuroAIDS.

Hauser KF, El-Hage N, Buch S, Berger JR, Tyor WR, Nath A, Bruce-Keller AJ, Knapp PE. Hauser KF, et al. Neurotox Res. 2005 Oct;8(1-2):63-80. doi: 10.1007/BF03033820. Neurotox Res. 2005. PMID: 16260386 Free PMC article. Review.

2

Oxidative stress and therapeutic approaches in HIV dementia.

Steiner J, Haughey N, Li W, Venkatesan A, Anderson C, Reid R, Malpica T, Pocernich C, Butterfield DA, Nath A. Steiner J, et al. Antioxid Redox Signal. 2006 Nov-Dec;8(11-12):2089-100. doi: 10.1089/ars.2006.8.2089. Antioxid Redox Signal. 2006. PMID: 17034352 Review.

3

Crystallographic studies of human MitoNEET.

Hou X, Liu R, Ross S, Smart EJ, Zhu H, Gong W. Hou X, et al. J Biol Chem. 2007 Nov 16;282(46):33242-33246. doi: 10.1074/jbc.C700172200. Epub 2007 Sep 27. J Biol Chem. 2007. PMID: 17905743 Free article.

4

Synergistic increases in intracellular Ca2+, and the release of MCP-1, RANTES, and IL-6 by astrocytes treated with opiates and HIV-1 Tat.

El-Hage N, Gurwell JA, Singh IN, Knapp PE, Nath A, Hauser KF. El-Hage N, et al. Glia. 2005 Apr 15;50(2):91-106. doi: 10.1002/glia.20148. Glia. 2005. PMID: 15630704 Free PMC article.

5

Selective isolation and purification of tat protein via affinity membrane separation.

Hollman AM, Christian DA, Ray PD, Galey D, Turchan J, Nath A, Bhattacharyya D. Hollman AM, et al. Biotechnol Prog. 2005 Mar-Apr;21(2):451-9. doi: 10.1021/bp049804z. Biotechnol Prog. 2005. PMID: 15801785

6

Acute migraine treatment with droperidol: A randomized, double-blind, placebo-controlled trial.

Silberstein SD, Young WB, Mendizabal JE, Rothrock JF, Alam AS. Silberstein SD, et al. Neurology. 2003 Jan 28;60(2):315-21. doi: 10.1212/01.wnl.0000042477.63516.b2. Neurology. 2003. PMID: 12552051 Clinical Trial.

7

Preferential vulnerability of astroglia and glial precursors to combined opioid and HIV-1 Tat exposure in vitro.

Khurdayan VK, Buch S, El-Hage N, Lutz SE, Goebel SM, Singh IN, Knapp PE, Turchan-Cholewo J, Nath A, Hauser KF. Khurdayan VK, et al. Eur J Neurosci. 2004 Jun;19(12):3171-82. doi: 10.1111/j.0953-816X.2004.03461.x. Eur J Neurosci. 2004. PMID: 15217373 Free PMC article.

8

CCL5/RANTES gene deletion attenuates opioid-induced increases in glial CCL2/MCP-1 immunoreactivity and activation in HIV-1 Tat-exposed mice.

El-Hage N, Bruce-Keller AJ, Knapp PE, Hauser KF. El-Hage N, et al. J Neuroimmune Pharmacol. 2008 Dec;3(4):275-85. doi: 10.1007/s11481-008-9127-1. Epub 2008 Sep 25. J Neuroimmune Pharmacol. 2008. PMID: 18815890 Free PMC article.

9

Silencing the PTEN gene is protective against neuronal death induced by human immunodeficiency virus type 1 Tat.

Zhao T, Adams MH, Zou SP, El-Hage N, Hauser KF, Knapp PE. Zhao T, et al. J Neurovirol. 2007 Apr;13(2):97-106. doi: 10.1080/13550280701236841. J Neurovirol. 2007. PMID: 17505978

10

Strong T cell type-1 immune responses to HIV-1 Tat (1-72) protein-coated nanoparticles.

Cui Z, Patel J, Tuzova M, Ray P, Phillips R, Woodward JG, Nath A, Mumper RJ. Cui Z, et al. Vaccine. 2004 Jun 30;22(20):2631-40. doi: 10.1016/j.vaccine.2003.12.013. Vaccine. 2004. PMID: 15193389

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

18 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Results by year